Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.
Marshall Crew, PhD, explores some of the key features of people and organizations that lead to the innovations and products, and hopes that by example, insights can be acquired that will be useful in his colleagues respective organizations and that might ultimately lead to more innovation in the industry.
Drug Development Executive: Cindy R. Kent, VP & General Manager of 3M DDSD, discusses her vision for the company and how developing trends are impacting the players in the pharmaceutical industry.
Wilfried Andrä, PhD, Pieter Saupe, and Matthias E. Bellemann, PhD, indicate the greatest obstacle on the road to targeted drug delivery in the GI tract was, until now, the lack of a practicable method to localize the capsule.
ADVANCED DELIVERY DEVICES – Incorporating Patient-Centric Design Into a Novel Anti-Needlestick Safety Device
Sarah Baer, MBA, says the market for biotechnology drugs continues to grow, and there is a need for pharmaceutical companies to offer injection devices that support both the complex properties of the biologic as well as the needs of the end-user who will be performing the injection.
INJECTABLE MICROEMULSIONS – Prolonged-Release Injectable Microemulsions: Opportunities for Pain Treatment
Rajesh Dubey, PhD, and Luigi G. Martini, FRPharmS, MBA, indicate available technologies do not support development of certain formulations to treat pain; however, microemulsions with their unique features, can provide a viable alternative to develop such formulations.
Drug Development Executive: Steven Damon, Founder of 4P Therapeutics, discusses his vision for the company and how 4P intends to create new and innovative transdermal products that meet the needs of patients, physicians, and payers.
SPECIAL FEATURE – Prefilled Syringes & Parenteral Contract Manufacturing – Product Differentiation Is Critical
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
ADVANCED DELIVERY DEVICES – Wearable Bolus Injectors – A New Class of Patient-Friendly Drug Delivery Systems
Michael D. Hooven, MSME, indicates bolus injectors represent one of the most exciting new opportunities in the field of medical devices, and his company’s focus on developing innovative technology in combination with an intense emphasis on Human Factors has resulted in a system that is unique in a number of ways.
EXCLUSIVE ONLINE CONTENT
Lonza recently announced a $93-million investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry…..
WEBINAR SERIES ALERT – Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts – Free Oct-Nov Webinar Series
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Proveris Scientific Research Collaboration: New Generation Technologies for Improved Measurement of Pharmaceutical Aerosols
Proveris Scientific Corporation recently announced its research collaboration with The University of Sydney and Macquarie University on a project to develop a new generation of technologies for improving….
Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….